Haemonetics
309 hedge funds and large institutions have $4.42B invested in Haemonetics in 2024 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 124 increasing their positions, 89 reducing their positions, and 42 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 89
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
17% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 42
3.48% more ownership
Funds ownership: 109.15% → 112.62% (+3.5%)
2% more call options, than puts
Call options by funds: $42.5M | Put options by funds: $41.7M
1% more funds holding
Funds holding: 306 → 309 (+3)
2% less capital invested
Capital invested by funds: $4.49B → $4.42B (-$70.9M)
Top Buyers
| 1 |
Neuberger Berman Group
New York
|
+$31.5M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$22.7M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$20.5M |
| 4 |
SCM
SG Capital Management
Chicago,
Illinois
|
+$18.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.5M |
Top Sellers
HAE Hedge Fund Activity: Q4 2024 in Review
309 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2024, worth a combined $4.42B — down 1.6% from $4.49B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new HAE positions and 42 closed out — a net gain of 7 holders — while 124 added to existing stakes and 89 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $31.5M. The largest seller was Brown Advisory, cutting an estimated $34.4M.
- 309 institutional investors held Haemonetics (HAE) as of Q4 2024, up from 306 in Q3 2024.
- Funds reported $4.42B of Haemonetics stock for Q4 2024, down 1.6% quarter-over-quarter.
- 49 funds opened new Haemonetics positions in Q4 2024 and 42 closed out, a net change of +7 holders.
- The largest Haemonetics buyer in Q4 2024 was Neuberger Berman Group, an estimated $31.5M added.
- The largest Haemonetics seller in Q4 2024 was Brown Advisory, an estimated $34.4M sold.
Based on aggregated 13F filings for Q4 2024.